Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

45

Revenue 2017

Zytiga

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Zytiga was produced by Janssen.

Taking a strategic approach

Taking a strategic approach But in oncology Zytiga (abiraterone) was last year not recommended for an early use indication in final draft guidance from NICE, but that appraisal process is currently on hold after Janssen

Astellas’ Xtandi cancer drug rejected by NICE

Astellas’ Xtandi cancer drug rejected by NICE England's pricing watchdog also currently recommends the chemotherapy agent docetaxel for the treatment of hormone-refractory metastatic prostate cancer, and Janssen's Zytiga (abiraterone) for certain patients with metastatic prostate

Prostate cancer treatment market to treble to £8.2bn by 2023

Prostate cancer treatment market to treble to £8.2bn by 2023 Canada – and is expected to be driven by a rapidly ageing population, the introduction of nine premium-priced therapies and the proposed label extensions for Zytiga and Xtandi the treatment of ... Mudbhary continued: “Zytiga is anticipated to lose

Pharma deals in February 2015

Pharma deals in February 2015 Challenges associated with turning this asset around e.g. complex production, sky-high price tag, looming competition from oral rivals Xtandi (Astellas) and Medivation) and Zytiga (J&J) will be daunting.

Sovaldi pushes Gilead to the top of US pharma list

Sovaldi pushes Gilead to the top of US pharma list The firm's drugs unit Janssen was bolstered by an array of new and diverse products, including its new hep C drug Olysio (simeprevir) and prostate cancer pill Zytiga (abiraterone acetate),

[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cegedim Health Data

Cegedim Health Data provides Real World Data and Evidence services to enable advancements in patient outcomes. With a data history...

Latest intelligence

Personalised medicine: driving a need for greater diversity in clinical trials
Kate Shaw, Innovative Trials' Founder & CEO, investigates one of the biggest challenges facing clinical research today....
Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...